Why a Weight-Loss Pill Is Still a Big Deal — Heard on the Street — Wall Street Journal
Weight-loss injections such as Wegovy and Zepbound have already reshaped medicine and raked in billions of dollars in sales — but they have barely scratched the surface. In the U.S. where adoption is highest, fewer than 1 in 10 adults are on a GLP-1 drug, despite nearly three-quarters being overweight or obese. Globally access is even more limited, held back by high costs, strict coverage requirements and supply shortages. A pill could change all that. Cheaper to make, easier to distribute and simpler to take, an oral weight-loss drug could finally bring obesity treatment to the masses. Wall Street, however, seems to have soured on the opportunity. On Thursday, Eli Lilly lost over $100 billion in market capitalization, with the stock falling 14% after the company reported underwhelming results for its much-anticipated pill, orforglipron. Patients on the highest dose of the drug lost an average of 12.4% of their body weight after more than a year. Lilly's injectable drug Zepbound ha...
Comments
Post a Comment